Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients
新型RIPK1抑制剂SAR443060 (DNL747)治疗神经退行性疾病的安全性、药代动力学和靶点结合：在健康受试者和患者中进行的随机、安慰剂对照、双盲I/Ib期研究
期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13317
Vissers, Maurits F J M; Heuberger, Jules A A C; Groeneveld, Geert Jan; Oude Nijhuis, Jerome; De Deyn, Peter Paul; Hadi, Salah; Harris, Jeffrey; Tsai, Richard M; Cruz-Herranz, Andres; Huang, Fen; Tong, Vincent; Erickson, Rebecca; Zhu, Yuda; Scearce-Levie, Kimberly; Hsiao-Nakamoto, Jennifer; Tang, Xinyan; Chang, Megan; Fox, Brian M; Estrada, Anthony A; Pomponio, Robert J; Alonso-Alonso, Miguel; Zilberstein, Moshe; Atassi, Nazem; Troyer, Matthew D; Ho, Carole
